KAINOS Laboratories (TSE:4556) EBIT: 円640 Mil (TTM As of Mar. 2026)


TSE:4556 KAINOS Laboratories Inc TSE:4556
39 GF Score
Price 円2,268.00
GF Value 円1,281.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is KAINOS Laboratories EBIT?

KAINOS Laboratories TSE:4556 39 EBIT is 円640 Mil as of Mar. 2026. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,281.99 (Significantly Overvalued). The stock has 6 warning signs investors should review.

KAINOS Laboratories's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円210 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円640 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. KAINOS Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 9.75%. KAINOS Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. KAINOS Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.01%.


KAINOS Laboratories  (TSE:4556) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

KAINOS Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=650.788 * ( 1 - 30.96% )/( (4997.286 + 4223.553)/ 2 )
=449.3040352/4610.4195
=9.75 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8900.912 - 596.521 - ( 3307.105 - max(0, 1551.301 - 5937.471+3307.105))
=4997.286

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9566.85 - 1169.067 - ( 4174.23 - max(0, 1963.36 - 6507.93+4174.23))
=4223.553

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

KAINOS Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=420.394/( ( (2494.515 + max(1329.065, 0)) + (2549.744 + max(643.987, 0)) )/ 2 )
=420.394/( ( 3823.58 + 3193.731 )/ 2 )
=420.394/3508.6555
=11.98 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1563.131 + 969.184 + 98.050999999999) - (596.521 + 0 + 704.78)
=1329.065

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1264.06 + 992.895 + 76.745000000001) - (1169.067 + 0 + 520.646)
=643.987

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

KAINOS Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=640.43/6401.013
=10.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KAINOS Laboratories EBIT Related Terms


KAINOS Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for KAINOS Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KAINOS Laboratories EBIT Chart

KAINOS Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 774.72 852.73 937.06 833.73 640.43

KAINOS Laboratories Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 405.11 477.80 355.93 430.23 210.20

TSE:4556 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KAINOS Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where KAINOS Laboratories's EV-to-EBIT falls into.


TSE:4556
39GF Score
KAINOS Laboratories Inc TSE:4556
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KAINOS Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円640 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円640 Mil mean?
KAINOS Laboratories (TSE:4556) has a EBIT of 円640 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on KAINOS Laboratories.
Is KAINOS Laboratories' EBIT too high?
KAINOS Laboratories' current EBIT is 円640 Mil. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' EBIT compare to ISRG and BDX?
KAINOS Laboratories' EBIT of 円640 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on KAINOS Laboratories. KAINOS Laboratories's current EBIT is 円640 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,281.99, compared to a current price of 円2,268.00 — trading 76.9% above its estimated fair value. The current EBIT is 円640 Mil. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current EBIT is 円640 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?

Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued. The current stock price of 円2,268.00 is trading 76.9% above its estimated GF Value™ of 円1,281.99. GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.

Key valuation signals for TSE:4556:

  • EBIT: 円640 Mil
  • GF Value™: 円1,281.99 vs. price of 円2,268.00 (76.9% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


KAINOS Laboratories Business Description

Address 38-18, Hongo 2-chome, Bunkyo-ku, Tokyo, JPN
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
39GF Score

Get the complete analysis for TSE:4556

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,268.00
Price
円1,281.99
GF Value